IBA SA :IBA to Install New Proteus®ONE Proton Therapy System in Taiwan
21 Décembre 2015 - 7:00AM
IBA to Install New
Proteus®ONE Proton Therapy System in Taiwan
Second contract signed with Tomorrow Medical Systems Co.
Ltd.
Louvain-la-Neuve,
Belgium, December 21st, 2015 -
IBA (Ion Beam Applications SA), the world's leading provider of
proton therapy solutions for the treatment of cancer, announces
today that it has signed a contract with TMS (Tomorrow Medical
Systems Co. Ltd.) for the installation of its single-room proton
therapy system Proteus®ONE* in
Taiwan.
The contract signed in Taipei,
includes the delivery of the Proteus®ONE
equipment as well a long term service and maintenance agreement
which together represents a value between EUR 30 to 35 million to
IBA. This is the second contract signed with TMS for an
installation of a proton therapy center in Taiwan. The first one
was signed in 2013.
TMS is part of the CHC Healthcare
Group (CHC), listed on the Taipei stock exchange. TMS operates
radiotherapy services for a number of medical centers in
Taiwan.
The Proteus®ONE system
has been developed by IBA to allow more patients globally to access
proton therapy. Proteus®ONE is a
smaller, less expensive and faster to install proton therapy
solution, encompassing the latest in proton therapy technologies,
including Pencil Beam Scanning.
Olivier Legrain,
Chief Executive Officer of IBA, commented: "This new contract demonstrates IBA's continued success in
Asia. Making proton therapy smaller and more affordable,
without jeopardizing cutting edge technology, is one of IBA's key
strategic goals and the Proteus®ONE system
does exactly that whilst continuing to provide the most accurate form of radiation therapy
available. We look forward to continue
working with our local partners in Taiwan to provide patients
across the region with access to the benefits of proton
therapy."
Pei-lin Lee,
President of CHC Group: "CHC is very happy to
partner with IBA to install a second Proteus®ONE
system in Taiwan. Proteus®ONE allows
patients to be treated with Intensity Modulated Proton Therapy
using Pencil Beam Scanning Technology which will greatly benefit
cancer patients in Taiwan."
***end***
About
Proteus®ONE
Proteus®ONE is the
compact intensity modulated proton therapy (IMPT) solution from
IBA. It benefits from the latest technologies developed with
renowned clinical institutions. Proteus®ONE is
smaller, more affordable, easier to install and to operate. It is
ultimately easier to finance, making this advanced radiation
therapy modality available to more institutions and patients
worldwide. Proteus®ONE makes
Proton Therapy easy.
About
IBA
IBA (Ion Beam Applications S.A.) is a global medical technology
company focused on bringing integrated and innovative solutions for
the diagnosis and treatment of cancer. The Company is the worldwide
technology leader in the field of proton therapy, the most advanced
form of radiation therapy available today. IBA's proton therapy
solutions are flexible and adaptable, allowing customers to choose
from universal full scale proton therapy centers as well as
compact, single room systems. In addition, IBA also has a
radiation dosimetry business and develops particle accelerators for
the medical world and industry.
Headquartered in Belgium and
employing about 1200 people worldwide, IBA has installed systems
across the world, from Europe and the US and to the emerging
markets. IBA is listed on the pan-European stock exchange
EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more
information can be found at: www.iba-worldwide.com
*
Proteus®ONE is the
brand name of a new configuration of the Proteus®235
About
CHC
CHC Healthcare Group (CHC) is a leading Taiwan full healthcare
service solution provider for high-end radiation therapy,
radiology, neurosurgery, ophthalmology and dentistry equipment.
Since 2009, CHC installations of radiotherapy equipment have
accounted for 80% of the total Taiwanese market. CHC is the
exclusive master distributor for a portfolio of global brand names
and has over 60+ certified experienced service engineers providing
world class after sales support and maintenance services. Website:
www.cyhc.com.tw
For further information please
contact:
IBA
Jean-Marc Bothy
Chief Financial Officer
+32 10 475 890
Investorrelations@iba-group.com
Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
Communication@iba-group.com |
For media and investor
enquiries:
Consilium Strategic Communications
Amber Fennell, Matthew Neal, Ivar Milligan
+44 (0) 20 3709 5700
IBA@consilium-comms.com
Rx Communications Group (US)
Melody Carey
+ 1 917 322 2571
mcarey@RxIR.com
|
PDF ENG - Taiwan P1 -
211215
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: IBA SA via Globenewswire
HUG#1974870
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024